Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Berkeley, USA
626 Bancroft Way
#3C
Berkeley, CA, 94710
USA

People

COO
Board Member
Board Member
Board Member
Board Member
Director of Clinical Operations
Director, Biodefense and Process Development
Director of Operations.
Show All People

Funding

TOTAL $36.5M
FUNDING TOTAL $36.5M
Venture Round, 11/2009
$2.95M
Venture Round, 4/2010
$769k
Series B, 4/2011
Morningside Group
$19.3M
Series B, 1/2013
$6.5M
Partial Close, 9/2013
$7M
Series C, 1/2014
Morningside Ventures
DEBT TOTAL $512k
Debt, 12/2011
$512k

Tags

Aduro BioTech

Aduro BioTech, Inc., a development stage biopharmaceutical company, engages in the development of early stage cancer therapies. The company focuses on the development of its minimally invasive NT and TNT cancer treatment systems, which use iron oxide nano-particles that generate heat when exposed to an externally applied magnetic field and kills tumor cells without the toxicity or collateral damage. It offers therapies for breast, prostate, colorectal, lung, pancreas, ovarian, and head and neck cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Recent Milestones

Videos

Screenshots

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
  3. Aduro BioTech Completes $19.25 Million Series B Financing (businesswire.com) [edit]
  4. SEC (sec.gov) [edit]
  5. Aduro Announces $6.5 Million Financing (businesswire.com) [edit]
  6. SEC (sec.gov) [edit]
  7. The Daily Startup: With Cancer Vaccine Data in Hand, Aduro BioTech Raising New Round (blogs.wsj.com) [edit]
Edit This Page
Last Edited 3/12/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy